Monoclonal antibody (mAb) products for intravenous (IV) administration generally require aseptic compounding with a commercial diluent within a pharmacy, prior to transport to the location of administration. The prepared dosing solution in the commercial diluent container (e.g., IV bag) may be transported to the dosing location via a pneumatic tube system (PTS) in hospital setting. The type and the levels of stresses associated with hospital PTS transportation are not well characterized thus far. There is also limited published information with respect to the impact of PTS stresses on product quality of mAbs.
In this presentation, I will summarize the type and the level of stresses associated with hospital PTS transportation method and their product quality impact for relatively sensitive and stable mAbs.
Learning Objectives:
Upon completion, participants will be able to understand the type and level of stresses associated with pneumatic tube system transportation method.
Upon completion, participants will be able to understand the impact of pneumatic tube system transportation method on product quality of mAbs.
Upon completion, participants will be able to learn about effective solutions / strategies to mitigate the product quality impact caused by the pneumatic tube system transportation method.